Factors Militating against Implementation of Value Reengineering in the Construction Industry

Autor: Winston WM Shakantu, Ibrahim M Jibrin, Ibrahim Saidu

Publikováno v: Journal of Engineering, Project, and Production Management, Vol 12, Iss 1, Pp 87-100 (2022)

Production improvement techniques in use by the Construction Industry (CI) in developing countries like Nigerian are yielding sub-optimal value for customers. This necessitated the investigation of techniques to engender maximum efficiency gains. Hen

Externí odkaz: https://doaj.org/article/ea6258e05ba247b39907076371ab38d3

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity.

Autor: Nirschl CJ; Werewolf Therapeutics, Watertown, Massachusetts., Brodkin HR; Werewolf Therapeutics, Watertown, Massachusetts., Domonkos C; Werewolf Therapeutics, Watertown, Massachusetts., Dwyer CJ; Werewolf Therapeutics, Watertown, Massachusetts., Hicklin DJ; Werewolf Therapeutics, Watertown, Massachusetts., Ismail N; Werewolf Therapeutics, Watertown, Massachusetts., Seidel-Dugan C; Werewolf Therapeutics, Watertown, Massachusetts., Steiner P; Werewolf Therapeutics, Watertown, Massachusetts., Steuert Z; Werewolf Therapeutics, Watertown, Massachusetts., Sullivan JM; Werewolf Therapeutics, Watertown, Massachusetts., Winston WM; Werewolf Therapeutics, Watertown, Massachusetts., Salmeron A; Werewolf Therapeutics, Watertown, Massachusetts.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2023 Jul 05; Vol. 11 (7), pp. 962-977.

Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.

Autor: Shirasuna K; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan. Electronic address: kenna.shirasuna@astellas.com., Koelsch G; Drug Discovery Research, Astellas Pharma Inc., 1 Astellas Way, Northbrook, IL 60062, USA., Seidel-Dugan C; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Salmeron A; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Steiner P; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Winston WM; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Brodkin HR; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Nirschl CJ; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Abbott S; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Kinugasa F; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan., Sugahara S; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan., Ohori M; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan., Takeuchi M; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan., Hicklin DJ; Potenza Therapeutics, 1030 Massachusetts Avenue, Suite 210, Cambridge, MA 02138, USA., Yoshida T; Drug Discovery Research, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.

Publikováno v: Cancer treatment and research communications [Cancer Treat Res Commun] 2021; Vol. 28, pp. 100433. Date of Electronic Publication: 2021 Jul 11.

Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.

Autor: Meetze K; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Vincent S; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Tyler S; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Mazsa EK; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Delpero AR; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Bottega S; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., McIntosh D; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Nicoletti R; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Winston WM; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Weiler S; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Feng B; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Gyuris J; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts., Weng Z; AVEO Pharmaceuticals, Inc., Cambridge, Massachusetts. zweng@aveooncology.com.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Mar 01; Vol. 21 (5), pp. 1106-14. Date of Electronic Publication: 2014 Dec 26.